Physician profile
James Maciejewski
NPI 1710204565
$1,627.52
in general payments reported to CMS, 2019-2025
22 companies · $59.24 in 2025
The $59.24 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.12 · 2020: $25.03 · 2021: $19.05 · 2022: $374 · 2023: $631 · 2024: $439 · 2025: $59.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $253.83 | 2019-2024 | Rybelsus, Ozempic, Tresiba |
| Inspire Medical Systems, INC. | $196.16 | 2022 | |
| Janssen Pharmaceuticals, INC | $160.57 | 2023-2024 | Xarelto |
| Boston Scientific Corporation | $139.61 | 2023-2024 | Watchman Flx |
| Merck Sharp & Dohme LLC | $111.54 | 2022-2023 | Verquvo, Belsomra, Gardasil 9 |
| Pfizer INC. | $102.96 | 2022-2025 | |
| Exact Sciences Corporation | $91.00 | 2023-2024 | Cologuard Collection Kit |
| Cardiva Medical, INC. | $85.21 | 2023 | Cardiva Vascade 6/7f Vcs |
| Glaxosmithkline, LLC. | $69.32 | 2022-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $64.99 | 2023-2024 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $55.55 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $54.42 | 2023 | Gemtesa |
| Alnylam Pharmaceuticals INC. | $49.09 | 2023-2024 | Onpattro |
| Philips North America LLC | $42.00 | 2024 | (Cm9) Amb Mon & Diag Und |
| Cvrx, INC. | $30.56 | 2022-2025 | Barostim Neo System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23.61 | 2019-2022 | |
| Urovant Sciences INC | $19.66 | 2022 | |
| Sk Life Science, INC. | $19.05 | 2021 | |
| Resmed Corp | $16.82 | 2025 | |
| Shield Therapeutics INC | $15.71 | 2024 | |
| Sanofi Pasteur INC. | $13.92 | 2019 | |
| Antares Pharma, INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Maciejewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.